These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 22444690)

  • 21. Hypoxic regulation of PFKFB-3 and PFKFB-4 gene expression in gastric and pancreatic cancer cell lines and expression of PFKFB genes in gastric cancers.
    Bobarykina AY; Minchenko DO; Opentanova IL; Moenner M; Caro J; Esumi H; Minchenko OH
    Acta Biochim Pol; 2006; 53(4):789-99. PubMed ID: 17143338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models.
    Benito J; Ramirez MS; Millward NZ; Velez J; Harutyunyan KG; Lu H; Shi YX; Matre P; Jacamo R; Ma H; Konoplev S; McQueen T; Volgin A; Protopopova M; Mu H; Lee J; Bhattacharya PK; Marszalek JR; Davis RE; Bankson JA; Cortes JE; Hart CP; Andreeff M; Konopleva M
    Clin Cancer Res; 2016 Apr; 22(7):1687-98. PubMed ID: 26603259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Impact of RNA interference targeting hypoxia-inducible factor-1alpha on chemosensitivity in esophageal squamous cell carcinoma cells under hypoxia].
    Wu XA; Sun Y; Fan QX; Wang LX; Wang RL; Zhang L
    Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(37):2640-4. PubMed ID: 18162154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte-osteoclast differentiation via induction of VEGF.
    Knowles HJ; Athanasou NA
    J Pathol; 2008 May; 215(1):56-66. PubMed ID: 18283716
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aberrant phenotype of plasmacytoid monocytes in acute myeloid leukemia.
    Boveri E; Castagnola C; Castello A; Magrini U
    Am J Hematol; 2008 May; 83(5):428-9. PubMed ID: 17617786
    [No Abstract]   [Full Text] [Related]  

  • 26. Residual bone marrow leukemic progenitor cell burden after induction chemotherapy in pediatric patients with acute lymphoblastic leukemia.
    Uckun FM; Stork L; Seibel N; Sarquis M; Bedros C; Sather H; Sensel M; Reaman GH; Gaynon PS
    Clin Cancer Res; 2000 Aug; 6(8):3123-30. PubMed ID: 10955793
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human TM9SF4 Is a New Gene Down-Regulated by Hypoxia and Involved in Cell Adhesion of Leukemic Cells.
    Paolillo R; Spinello I; Quaranta MT; Pasquini L; Pelosi E; Lo Coco F; Testa U; Labbaye C
    PLoS One; 2015; 10(5):e0126968. PubMed ID: 25961573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Hypoxia increases the expression of heparitinase and the invasiveness through the hypoxia inducible factor-1alpha dependent pathway in human ovarian cancer cell line SKOV3].
    Yuan CX; Gu S; Zhang SH; Zhang XN
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Dec; 30(6):711-6. PubMed ID: 19180921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Myeloperoxidase expression as a potential determinant of parthenolide-induced apoptosis in leukemia bulk and leukemia stem cells.
    Kim YR; Eom JI; Kim SJ; Jeung HK; Cheong JW; Kim JS; Min YH
    J Pharmacol Exp Ther; 2010 Nov; 335(2):389-400. PubMed ID: 20699435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypoxia-inducible factor-1α protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia.
    Deeb G; Vaughan MM; McInnis I; Ford LA; Sait SN; Starostik P; Wetzler M; Mashtare T; Wang ES
    Leuk Res; 2011 May; 35(5):579-84. PubMed ID: 21176961
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of YC-1 on hypoxia-inducible factor 1-driven transcription activity, cell proliferative vitality, and apoptosis in hypoxic human pancreatic cancer cells.
    Zhao Q; Du J; Gu H; Teng X; Zhang Q; Qin H; Liu N
    Pancreas; 2007 Mar; 34(2):242-7. PubMed ID: 17312464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia.
    Hämäläinen MM; Kairisto V; Juvonen V; Johansson J; Aurén J; Kohonen K; Remes K; Salmi TT; Helenius H; Pelliniemi TT
    Eur J Haematol; 2008 Mar; 80(3):201-7. PubMed ID: 18081724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia.
    Konopleva M; Thall PF; Yi CA; Borthakur G; Coveler A; Bueso-Ramos C; Benito J; Konoplev S; Gu Y; Ravandi F; Jabbour E; Faderl S; Thomas D; Cortes J; Kadia T; Kornblau S; Daver N; Pemmaraju N; Nguyen HQ; Feliu J; Lu H; Wei C; Wilson WR; Melink TJ; Gutheil JC; Andreeff M; Estey EH; Kantarjian H
    Haematologica; 2015 Jul; 100(7):927-34. PubMed ID: 25682597
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Humanized model to study leukemic stem cells.
    Bonnet D
    Methods Mol Biol; 2009; 538():247-62. PubMed ID: 19277589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multistep targeted nano drug delivery system aiming at leukemic stem cells and minimal residual disease.
    Shi Y; Su Z; Li S; Chen Y; Chen X; Xiao Y; Sun M; Ping Q; Zong L
    Mol Pharm; 2013 Jun; 10(6):2479-89. PubMed ID: 23646913
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cellular pharmacokinetics of daunomycin in human leukemic blasts in vitro and in vivo.
    Scheulen ME; Kramer B; Skorzec M; Reich WK
    Haematol Blood Transfus; 1990; 33():122-8. PubMed ID: 2323624
    [No Abstract]   [Full Text] [Related]  

  • 37. N-Cadherin Aided in Maintaining the Characteristics of Leukemic Stem Cells.
    Zhi L; Gao Y; Yu C; Zhang Y; Zhang B; Yang J; Yao Z
    Anat Rec (Hoboken); 2016 Jul; 299(7):990-8. PubMed ID: 27064800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypoxia-CXCL6 axis affects arteriolar niche remodeling in acute myeloid leukemia.
    Li L; Man J; Zhao L
    Exp Biol Med (Maywood); 2021 Jan; 246(1):84-96. PubMed ID: 33167688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monitoring of WT1 and its target gene IRF8 expression in acute myeloid leukemia and their significance.
    Zhang Q; Zhang Q; Li Q; Liu B; Wang Y; Lin D; Zhou C; Li W; Tang K; Tian Z; Wang M; Wang J; Mi Y
    Int J Lab Hematol; 2015 Aug; 37(4):e67-71. PubMed ID: 25387409
    [No Abstract]   [Full Text] [Related]  

  • 40. Residual Disease in a Novel Xenograft Model of RUNX1-Mutated, Cytogenetically Normal Acute Myeloid Leukemia.
    Sivagnanalingam U; Balys M; Eberhardt A; Wang N; Myers JR; Ashton JM; Becker MW; Calvi LM; Mendler JH
    PLoS One; 2015; 10(7):e0132375. PubMed ID: 26177509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.